Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2011-08-09
2011-08-09
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120, C436S089000
Reexamination Certificate
active
07993824
ABSTRACT:
The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5436131 (1995-07-01), Condra et al.
patent: 5766842 (1998-06-01), Melnick et al.
patent: 5837464 (1998-11-01), Capon et al.
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6103462 (2000-08-01), Paulous et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 2002/0064838 (2002-05-01), Parkin et al.
patent: 2003/0108857 (2003-06-01), Parkin et al.
patent: WO99/67427 (1999-06-01), None
patent: WO00/78996 (2000-12-01), None
patent: WO02/22076 (2002-03-01), None
patent: WO02/068618 (2002-09-01), None
patent: WO02/099387 (2002-12-01), None
patent: WO03/070700 (2003-08-01), None
patent: WO2004/003512 (2004-01-01), None
patent: WO2004/003514 (2004-01-01), None
Robinson L. HIV Type 1 Protease Cleavage Site Mutations and Viral Fitness: Implications for Drug Susceptibility Phenotyping Assays. AIDS Research and Human Retroviruses 2000, vol. 16, No. 12, pp. 1149-1156.
Schmidt B. Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease Inhibitors. Antimicrobial Agents and Chemotherapy 2000, vol. 44, No. 11, pp. 3213-3216.
Deeks, S. Novel Four-Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor-Containing Regimen. The Journal of Infectious Diseases 1999, vol. 179, pp. 1375-1381.
Croteau, G. Impaired Fitness of Human Immunodeficiency Virus Type 1 Variants with High-Level Resistance to Protease Inhibitors. Journal of Virology 1997, vol. 71, No. 2, pp. 1089-1096.
Jorgensen L. Accession No. CAB94359. [online]. National Center for Biotechnology Information [retrieved on Feb. 2, 2006]. Retrived from the Internet <URL: www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=8517576>.
Mascolini M. Revisiting Resistance. IAPAC Monthly Aug. 2000. [online] International Association of Physicians in AIDS Care [retrieved on Feb. 2, 2006]. Retrieved fro the internet <www.iapac.org/home.asp?pid=76&toolid=2&itemid=3317#11>.
Colonno R. Susceptibility Data on Clinical Isolates: NFV. [online] HIV Drug Reistance Database [retrieved on Feb. 2, 2006]. Retrieved from the internet <URL: hivdb.stanford.edu/cgi-bin/GetResiData.cgi?type=allClinicalPhenotype&drug=NFV&class=Pl&pos=84>.
Beerenwinkel N. Accession No. AAK32197. [online]. National Center for Biotechnology Information [retrieved on Feb. 2, 2006]. Retrived from the Internet <URL: www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=protein&cmd=search&term=AAK32197>.
Paulsen et al. Amprenavir and Lopinvir cross-resistance in HIV-1 from subjects failing protease inhibitor therapies. 5th International Workshop on HIV Drug Resistance & Treatment Strategies Jun. 4-8, 2001 Antiviral Therapy vol. 6 Suppl. 1, 51-52.
Gilden D. Retrovirus Conference Report: Three New Agents to the Rescue [online]. Jan. 1999 [retrieved on Sep. 1, 2010]. Retrieved from the Internet:<URL: http://www.thebody.com/content/treat/art13551.html>.
Bowie et al. Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions. Science, New Series, 1990, vol. 247, No. 4948, pp. 1306-1310.
Colonno et al. Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens. Journal of Infectious Diseases, May 15, 2004, vol. 189, pp. 1802-1810.
Condra et al., (1996), “Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor ,”Journal of Virology, 70(12): 8270-76.
Genbank Accession No. AF324493 HIV-1 vector pNL4 . . . [gi:12831134] (2001).
Gervaix et al., (1997), “A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility in Vitro,”Proc. Natl. Acad. Sci. USA, 94:4653-4658.
Gong et al., (2000), “In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632,”Antimicrobial Agents and Chemotherapy, 44(9): 2319-26.
Gunthard et al., (1998), “Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1polFrom Clinical Samples”,Aids Research and Human Retroviruses, 14(10): 869-876.
Haubrich et al., (2001), “CCTG 575: A Randomized. Prospective Study of Phenotype Testing Versus Standard of Care For Patients Failing Antiretroviral Therapy;”Antiviral Therapy, 6(Supplement 1): 63.
Herrmann et al., (1997), “A Working Hypotheses-Virus Resistance Development As an Indicator of Specific Antiviral Activity,”Ann. NY Acad Sciences, 284: 632-637.
Hertogs et al., (1998), “A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs,”Antimicrobial Agents and Chemotherapy, 42(2): 269-276.
Hirsch et al., (2000), “Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection,”JAMA, 283(18): 2417-26.
Katzenstein et al., (2002), “Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364,” Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection,2002 9thConference on Retroviruses and Opportunistic Infections, Session 77 Poster Session 591-T.
Katzenstein et al., (2002), “The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy,”2002 9thConference on Retroviruses and Opportunistic Infections, Session 28 Poster Session 129.
Maguire et al., (2002), “Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors,”Antimicrobial Agents and Chemotherapy, 46(3): 731-738.
Petropoulos et al., (2000), “A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1,”Antimicrobial Agents and Chemotherapy, 44(4): 920-928.
Int'l Search Report for PCT/US03/21335, May 3, 2004.
Race et al., (1999), “Analysis of HIV Cross-Resistance to Protease Inhibitors Using a Rapid Single-Cycle Recombinant Virus Assay for Patients Failing on Combination Therapies,”AIDS, 13(15): 2061-2068.
Schuurman et al., (1999), “Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase,”Journal of Clinical Microbiology, 37(7): 2291-2296.
Shi et al., (1997), “A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors,”Antimicrobial Agents and Chemotherapy, 41(12): 2781-85.
Carrillo et al., (1998), “In Vitro Selection and Characterization of Human Immunodefciency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor,”Journal of Virology, 72(9): 7532-41.
Craig et al., 1998 “HIV Protease Genotype and Viral Sensitivity to HiV Protease Inhibito
Chappey Colombe
Parkin Neil T.
Petropoulos Christos J.
Humphrey Louise
Kilpatrick Townsend & Stockton
Lucas Zachariah
Monogram Biosciences, Inc.
LandOfFree
Compositions and methods for determining the susceptibility... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for determining the susceptibility..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for determining the susceptibility... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630169